LongevitySignal
Subscribe
🧬

Biotech

Biotech startups, drug therapies, senolytics, and FDA approvals.

Biotechyesterday

Exploring the Connection Between Big Pharma and Gray-Market Peptides

A recent analysis reveals significant ties between the pharmaceutical industry and gray-market peptides, highlighting a complex relationship that goes beyond public perception. The study traced the patent and development histories of 25 popular compounds, uncovering deeper connections to big pharma than previously understood. This relationship raises important questions about the safety and efficacy of these peptides for health optimization.

Biotech2d ago

Kailera Completes Enrollment for Obesity Trials, Results Expected in 2028

Kailera has completed enrollment for its three Phase 3 trials of ribupatide, a weekly injection aimed at treating obesity. Approximately 4,900 participants will be involved in the trials, which will compare ribupatide against semaglutide. Results from these trials are anticipated to be released in mid-2028.

Biotech2d ago

Longeveron’s Stem Cell Therapy Shows Promise for Reducing Brain Inflammation in Alzheimer’s Patients

Longeveron has released new preclinical data suggesting that its stem cell therapy may lead to reduced brain inflammation in individuals with Alzheimer's disease. This finding comes from a reevaluation of data from the company's CLEAR MIND trial, which involved 49 participants. As Longeveron prepares for an investor tour, the implications of these findings could be significant for future Alzheimer's treatments.

Biotech2d ago

Heart Pill Reduces Inflammation Markers in Initial Study

Monte Rosa's NEK7-targeting drug has shown promise in reducing several heart-risk biomarkers in a trial involving 108 individuals with obesity. The drug works by targeting the NLRP3 inflammasome, which plays a key role in the inflammatory response linked to various health conditions, including heart disease. This early trial suggests potential benefits for those at risk of cardiovascular issues.

Biotech2d ago

Digbi Health Integrates Gut Data with Menopause Insights

Digbi Health has expanded its Precision Biology platform to include hormone replacement therapy (HRT) and has released results from nearly 16,000 members regarding irritable bowel syndrome (IBS). The company aims to leverage its extensive gut health data to provide insights specifically related to menopause. This development marks a significant step in understanding the intersection of gut health and hormonal changes during menopause.

Biotech2d ago

Big Pharma Shifts Focus from Development to Acquisition

Recent findings indicate that major pharmaceutical companies are increasingly opting to acquire existing innovations rather than develop new drugs in-house. This trend is driven by challenges such as patent cliffs and declining research and development productivity. The Longevity Biotech Report reveals that the largest drugmakers control 62% of all registered biotech companies, highlighting their strategy of buying into existing scientific advancements.

Biotech2d ago

Tenvie Therapeutics Initiates Phase 1 Study of Brain-Penetrating Drug TNV313

On October 13, 2026, Tenvie Therapeutics announced the dosing of the first subject in a Phase 1 clinical trial for TNV313, a new brain-penetrating drug. This randomized ascending dose study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in healthy volunteers, while also validating its distribution in the central nervous system (CNS). The trial will assess both single and multiple oral doses and explore pharmacodynamic biomarkers.

Biotech2d ago

Digbi Health Expands Precision Biology Care Nationwide

Digbi Health has launched its precision biology telehealth platform across all 50 states, partnering with OpenLoop Health and MD Integrations. This expansion allows members from over 300 employers and health plans to access a network of more than 700 healthcare professionals, including physicians and nurse practitioners. The services include GLP-1 medications and hormone replacement therapy, aimed at enhancing personalized health care.

Biotech2d ago

Inmune Bio Partners with Quantum Computing Inc. for Alzheimer's Research

Inmune Bio has announced a collaboration with Quantum Computing Inc. to leverage quantum computing and artificial intelligence in Alzheimer's research. The partnership aims to utilize Inmune Bio's extensive clinical datasets alongside QCi's quantum optimization technology to identify new applications for their drug candidate, XPro, and explore potential biomarkers associated with Alzheimer's disease. This innovative approach could enhance the understanding and treatment of neurodegenerative diseases.

Biotech3d ago

Cellino Team Launches Immune Cell Banking Service

The Cellino team has introduced a new service that allows individuals to bank their immune cells for potential future therapies. This initiative aims to preserve the youngest immune cells currently circulating in the bloodstream, potentially offering valuable resources for health optimization and longevity in the future.

Biotech3d ago

XPRIZE Awards $1 Million to Mitochondrial Drug Research Team

Mighty Therapeutics, in collaboration with the University of Washington, has received a $1 million grant from the XPRIZE Healthspan competition to advance research on elamipretide, a mitochondrial drug. The funding will support the design of a larger clinical trial aimed at older adults, utilizing pilot data to inform the study's framework. This initiative is part of a broader effort to enhance healthspan and longevity through innovative therapies.

Biotech3d ago

Review Highlights Animal Study Evidence for Mesenchymal Stem Cell Therapy in Neurodegeneration

A recent review assesses the animal study evidence for mesenchymal stem cell (MSC) therapy in treating neurodegenerative diseases and stroke. While results indicate that these therapies can modulate chronic inflammation, outcomes in human trials have been mixed, suggesting variability based on manufacturing and logistical factors. The findings underscore the need for further research to clarify the efficacy of MSC therapies in humans.

Biotech3d ago

Sironax Phase 2 Trial Reaches Half Enrollment for SIR4156 Obesity Study

Sironax has announced that it has achieved approximately 50% enrollment in its global Phase 2 FORGE-LM trial for SIR4156, an allosteric NAMPT activator. This study is evaluating the drug in combination with semaglutide for adults with obesity. The trial aims to assess the impact of SIR4156 on body weight and metabolic health.

Biotech3d ago

Rona Therapeutics Licenses RNAi Drug for Selective Fat Loss to Roche in $1.1 Billion Agreement

Rona Therapeutics has entered into a significant licensing agreement with Roche, granting the pharmaceutical giant exclusive rights to its investigational RNA interference (RNAi) drug targeting activin receptor-like kinase 7 (ALK7). This drug aims to selectively reduce visceral and ectopic fat while preserving lean mass, potentially offering a new approach to fat loss that could benefit health optimization efforts.

Biotech4d ago

Alzheimer’s Drug Market Projected to Reach $14.7 Billion by 2033

The Alzheimer’s drug market is expected to grow rapidly, reaching an estimated $14.7 billion by 2033, driven by the introduction of disease-modifying therapies. This shift marks a significant change from traditional treatments, which primarily focused on symptom management. As healthcare systems grapple with the costs associated with these new therapies, the landscape of Alzheimer's treatment is poised for transformation.

Biotech4d ago

Atrogi's Muscle Pill Shows Early Promise in Small Study

A small open-label study of Atrogi's muscle pill, ATR-258, has shown promising results in 13 participants over an eight-week period. The study reported fat loss, gains in lean mass, and improved leg power, although it lacked a placebo group for comparison. These findings suggest potential benefits for individuals looking to optimize muscle health while managing weight.

Biotech4d ago

QIMA Life Sciences Launches SQINGEVITY to Test Longevity Claims in Cosmetics

QIMA Life Sciences has introduced SQINGEVITY, a new initiative that combines biological testing and clinical studies to evaluate the effectiveness of cosmetics in addressing skin and hair aging. This development marks a shift in the beauty industry, which has traditionally focused on aesthetic outcomes rather than cellular impacts. The initiative aims to provide scientific validation for longevity claims made by cosmetic products.

Biotech4d ago

Dental Pulp Stem Cell Secretome Shows Promise for Stroke Recovery

Recent research indicates that the secretome derived from dental pulp stem cells may enhance recovery outcomes following a stroke in mice. This approach focuses on utilizing the signaling molecules released by stem cells rather than the cells themselves, potentially leading to more effective therapies. The findings suggest a new avenue for treatment strategies aimed at improving neurological recovery after stroke.

Biotech4d ago

IBIO-610 and Semaglutide Show Promise for Targeted Fat Loss and Muscle Preservation

A recent study by IBio has demonstrated that combining IBIO-610 with semaglutide results in a significant reduction in fat loss while preserving lean muscle mass. In an eight-week trial involving obese nonhuman primates, the combination therapy showed that 93% of the weight lost was fat, compared to 77% with semaglutide alone. This finding suggests a potential advancement in obesity treatment strategies that prioritize muscle retention.

Biotech4d ago

Cognition Therapeutics Secures Patent for Zervimesine Until 2045

Cognition Therapeutics has been awarded a patent for a new crystalline form of zervimesine (CT1812) by the United States Patent and Trademark Office. This patent, numbered 12,759,979, is set to expire in 2045, with the possibility of a five-year extension contingent on FDA approval. The patent is intended to protect the composition of matter related to this novel treatment.

Biotech4d ago

United Therapeutics Presents New Data at CHEST 2026

United Therapeutics is set to present new findings at the CHEST 2026 Annual Meeting, taking place from October 18-21, 2026, in Phoenix, Arizona. The company will deliver two oral presentations and five poster presentations, along with sponsoring a symposium focused on emerging data and screening insights in pulmonary hypertension associated with interstitial lung disease (PH-ILD). A notable highlight includes a pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study.

Biotech5d ago

Abu Dhabi Initiates Biological Age Assessment Partnership with Ultrahuman

Abu Dhabi has launched a two-year partnership with Ultrahuman to integrate clinical biomarkers and wearable data for assessing biological age. This initiative aims to enhance public health by providing a more accurate understanding of aging within the population, moving beyond traditional age metrics. The collaboration seeks to bring aging assessment into public health discussions, potentially influencing health optimization strategies.

Biotech5d ago

Variant Bio Expands AI Genetics Partnership to Cardiovascular Health

Variant Bio has extended its partnership with Boehringer Ingelheim to include cardiovascular targets, building on their existing work in kidney disease. This collaboration could be worth over $250 million and aims to leverage genetic insights to develop new treatments. The initiative highlights the growing intersection of artificial intelligence and genetics in the pursuit of health optimization.

Biotech5d ago

Immorta Bio Advances AI-Designed Senolytic Immunotherapy SenoMune-0257

Immorta Bio has completed preclinical studies for SenoMune-0257, an AI-designed peptide immunotherapy aimed at targeting senescent cells. The therapy is designed to enhance immune recognition and elimination of these cells while preserving healthy ones. The company plans to move into clinical development by 2026.

Biotech5d ago

Rubedo Life Sciences Reports Significant Reduction in Skin Epigenetic Age from Phase 1b Trial

Rubedo Life Sciences has announced promising results from its Phase 1b clinical trial of RLS-1496, a topical treatment for atopic dermatitis. The study demonstrated a statistically significant mean reduction of 2.1 years in skin epigenetic age after four weeks of treatment, with some participants experiencing even greater reductions. These findings suggest potential implications for skin health and cellular senescence.

Biotech6d ago

Sava Secures $36 Million for Glucose Sensor Development

Sava has successfully raised $36 million in a Series A funding round, led by Ascensia Diabetes Care, to advance the development of its innovative glucose microsensor. This partnership aims to facilitate the launch of the device in Europe, with potential applications extending beyond glucose monitoring. The technology could significantly reduce the need for traditional fingerstick blood tests.

Biotech6d ago

New Initiative Aims to Reduce Alzheimer's Diagnosis Wait Times in the UK

A new partnership in the UK is set to address the lengthy diagnosis wait for Alzheimer's disease by integrating a blood test, a cognitive app, and national healthcare infrastructure. Currently, individuals in the UK experience an average wait of three and a half years from the onset of symptoms to receiving a formal diagnosis. This initiative seeks to streamline the process and provide earlier intervention for those affected.

Biotech6d ago

Oxford Biotech Secures Funding for Cell-Based mRNA Manufacturing

A biotech company from Oxford has raised $47 million to enhance cell-based mRNA manufacturing processes. This initiative aims to improve therapies that require repeated dosing, moving away from traditional in vitro transcription methods that dominate current mRNA production. The shift to cell-based production could have significant implications for the development of future mRNA therapies.

Biotech6d ago

Regulatory Developments in Aging Research

The FDA and EMA currently do not recognize aging as a medical indication, but recent discussions suggest a shift may be on the horizon. As of mid-2026, there are no established biomarkers for biological age, yet the groundwork for potential regulatory changes is being laid. This could open new avenues for research and treatment in the field of longevity.

Biotech6d ago

European Consortium Develops Ultra-Thin Brain Implant for Parkinson's Treatment

The MINIGRAPH consortium, supported by the European Innovation Council, has created an ultra-thin brain implant designed to treat Parkinson's disease. This innovative technology features graphene neural interfaces, implantable electronics, and autonomous software, along with a magnetically guided robotic implantation procedure. The consortium includes several prominent research institutions and aims to enhance clinical translation for Parkinson's treatment.

BiotechOct 10

Regenxbio's Gene Therapy Demonstrates Long-Term Efficacy in Diabetic Retinopathy

Regenxbio has reported three-year durability data for its gene therapy, Surabgene (lomparvovec), in treating non-proliferative diabetic retinopathy. The findings, presented at the Retina Society's 59th Annual Scientific Meeting, indicate that a single suprachoroidal administration of the therapy resulted in sustained efficacy over the follow-up period from the Phase II ALTITUDE study. This development could represent a significant advancement in the management of diabetic retinopathy.

BiotechOct 10

Longevity Biotech's 100x Question Explored

The recent Longevity Biotech Report highlights the potential financial returns associated with longevity investments, suggesting a 100x return on investment. However, it raises critical questions about who will benefit from these advancements in longevity biotech. Sponsored by MuseCell Innovations, the report emphasizes the need for clarity on the distribution of these potential profits.

BiotechOct 9

Biological Age Test to Guide GLP-1 Prescriptions via New Telehealth Platform

Deep Longevity has launched a telehealth platform called Accrua, which utilizes a blood-based biological age score to inform treatment plans for GLP-1 prescriptions. This innovative approach involves quarterly re-testing to monitor changes in biological age, suggesting that blood tests can provide a more accurate reflection of an individual's age than traditional methods. The platform aims to enhance personalized healthcare by aligning treatment strategies with biological metrics.

BiotechOct 9

Genentech Invests $100M in Alector's Parkinson's Therapy AL050

Genentech has made a significant investment of $100 million upfront in Alector's Parkinson's disease therapy, AL050, which is still in development. This deal could potentially expand to $1.17 billion with milestone payments as the therapy progresses toward clinical trials. The collaboration highlights the ongoing efforts to address neurodegenerative diseases, particularly Parkinson's.

BiotechOct 9

Tiny Health Secures $33 Million to Expand Microbiome Testing Services

Tiny Health, an Austin-based microbiome testing company, has successfully raised $33 million in an oversubscribed Series B funding round led by B Capital. Originally focused on testing the gut health of infants, the company has shifted its focus to adult testing, which now surpasses pediatric testing in volume. This funding will support the company's efforts to enhance its microbiome analysis capabilities and expand its market reach.

BiotechOct 9

Alzinova’s Alzheimer’s Vaccine Advances to CTAD Stage

Swedish biotech company Alzinova is set to present the design of its Phase II ADVANCE trial for the Alzheimer’s vaccine candidate ALZ-101 at the upcoming CTAD conference in Boston. Although trial results are not yet available, the company is confident in the study design it will showcase. This presentation marks a significant step in the ongoing effort to develop effective treatments for Alzheimer’s disease.

BiotechOct 9

FDA Discusses Phase 3 Trial Metrics for Lewy Body Drug Zervimesine

Cognition Therapeutics is set to meet with the FDA on October 20 to finalize the success metrics for a Phase 3 trial of zervimesine, a drug targeting dementia with Lewy bodies (DLB). This meeting is crucial as DLB can present with hallucinations before more typical cognitive decline occurs, highlighting the need for effective treatments. The outcome of these discussions may set a precedent for future drug approvals in this area.

BiotechOct 9

AgelessRx Launches GHK-Cu Cream for Age-Related Skin Repair

AgelessRx has introduced GHK-Cu Cream, a prescription copper peptide cream aimed at aiding tissue repair and renewal that diminishes with age. The cream is available in clinician-guided concentrations of 0.5% and 3%, allowing healthcare providers to tailor treatments based on individual patient needs. This product represents a new option for those seeking to address age-related skin changes.

BiotechOct 9

Cellular Rejuvenation Technology Advances to Human Trials

A new cellular rejuvenation therapy, ER-100, has entered human trials, showing promising early results in glaucoma patients. This therapy aims to reverse epigenetic drift associated with aging without pushing cells to pluripotency. The initial data indicates potential benefits for age-related conditions, marking a significant step in longevity research.

BiotechOct 8

Novartis Advocates for Regenerative Approaches in Longevity Research

Fiona Marshall, President of Biomedical Research at Novartis, emphasizes the need for big pharmaceutical companies to prioritize regenerative medicine over traditional methods that merely slow the aging process. Her insights were shared during a recent longevity meeting, highlighting the potential for innovative therapies to enhance healthspan and lifespan. This shift could significantly impact the future of longevity research and treatment options.

Newsletter

Your weekly longevity signal. No spam.